The Implantable Cardioverter Defibrillator: Technical and Clinical Considerations

Chapter

Abstract

The implantable cardioverter defibrillator (ICD) has become the most common device implanted for the treatment of arrhythmia disorders. The enormous technological development of these devices is perhaps the most dramatic progression observed in medicine over the last 30 years. The initial experiments of Mirowski published in 1978 required an external unit developed into epicardial patches and a large abdominal human implantable device released in 1985 and this yielded to transvenous leads in the early 1990s and smaller pectoral and dual chamber devices in the late 1990s and ultimately to combine cardiac resynchronization devices with defibrillation in the first few years of the new millennium.

The aim of this chapter is to review the current ICD indications based on the results of the most recent published trials, comment about the technical aspects involved in the design, implant and testing of the devices and an overview of the follow up recommendations.

Keywords

Implantable Cardioverter Defibrillator Sudden Cardiac Death ICD Defibrillation Antitachycardia Pacing Shock therapy DFT Telemetry 

References

  1. 1.
    Mirowski M, Mower MM, Langer A, Heilman MS, Schreibman J. A chronically implanted system for automatic defibrillation in active conscious dogs. Experimental model for treatment of sudden death from ventricular fibrillation. Circulation. 1978;58(1):90–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Device@FDA, U.S. Food and Drug Administration/Center for Devices and Radiological Health. http://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/
  3. 3.
    Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee on Pacemaker Implantation). Circulation. 2002;106:2145–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based ­therapy of cardiac rhythm abnormalities. Heart Rhythm. 2008;5:e1–62.PubMedCrossRefGoogle Scholar
  5. 5.
    Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341(25):1882–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Bardy GH, Lee K, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(20):2146.Google Scholar
  11. 11.
    Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–95.PubMedCrossRefGoogle Scholar
  13. 13.
    Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.PubMedCrossRefGoogle Scholar
  14. 14.
    A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337(22):1576–83.Google Scholar
  15. 15.
    Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297–302.PubMedCrossRefGoogle Scholar
  16. 16.
    Sheldon R, Connolly S, Krahn A, Roberts R, Gent M, Gardner M. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation. 2000;101(14):1660–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Wilkoff BL. Implantable cardioverter-defibrillator: technical aspects. In: Douglas JJ, Zipes P, editors. Cardiac electrophysiology: from cell to bedside. Phyladelphia: Saunders; 2004. p. 970–9.Google Scholar
  19. 19.
    Usui M, Walcott GP, KenKnight BH, Walker RG, Rollins DL, Smith WM, et al. Influence of malpositioned transvenous leads on defibrillation efficacy with and without a subcutaneous array electrode. Pacing Clin Electrophysiol. 1995;18(11):2008–16.PubMedCrossRefGoogle Scholar
  20. 20.
    Stajduhar KC, Ott GY, Kron J, McAnulty JH, Oliver RP, Reynolds BT, et al. Optimal electrode position for transvenous defibrillation: a prospective randomized study. J Am Coll Cardiol. 1996;27(1):90–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Bardy GH, Johnson G, Poole JE, Dolack GL, Kudenchuk PJ, Kelso D, et al. A simplified, single-lead unipolar transvenous cardioversion-defibrillation system. Circulation. 1993;88(2):543–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Higgins SL, Alexander D, Kuypers CJ, Brewster SA. The subcutaneous array: a new lead adjunct for the transvenous ICD to lower defibrillation thresholds. Pacing Clin Electrophysiol. 1995;18(8):1540–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Kettering K, Mewis C, Dornberger V, Vonthein R, Bosch RF, Seipel L, et al. Long-term experience with subcutaneous ICD leads: a comparison among three different types of subcutaneous leads. Pacing Clin Electrophysiol. 2004;27(10):1355–61.PubMedCrossRefGoogle Scholar
  24. 24.
    Cesario D, Bhargava M, Valderrabano M, Fonarow GC, Wilkoff B, Shivkumar K. Azygos vein lead implantation: a novel adjunctive technique for implantable cardioverter defibrillator placement. J Cardiovasc Electrophysiol. 2004;15(7):780–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Markewitz A, Kaulbach H, Mattke S, Dorwarth U, Hoffmann E, Weinhold C, et al. The left subclavian vein as an alternative site for implantation of the second defibrillation lead. Pacing Clin Electrophysiol. 1995;18(3 Pt 1):401–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Mouchawar GA, Wolsleger W, Doan PD, Causey 3rd JD, Kroll MW. Does an SVC electrode further reduce DFT in a hot-can ICD system? Pacing Clin Electrophysiol. 1997;20(1 Pt 2):163–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Tomassoni G, Newby K, Moredock L, Rembert J, Natale A. Effect of the superior vena cava electrode surface area on defibrillation threshold in different lead systems. Pacing Clin Electrophysiol. 1998;21(1 Pt 1):94–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Thal S, Thai H. Elevated defibrillation threshold: are defibrillation vectors important? Rev Argent Cardiol. 2011;79:182–5.Google Scholar
  29. 29.
    Fotuhi PC, Kenknight BH, Melnick SB, Smith WM, Baumann GF, Ideker RE. Effect of a passive endocardial electrode on defibrillation efficacy of a nonthoracotomy lead system. J Am Coll Cardiol. 1997;29(4):825–30.PubMedCrossRefGoogle Scholar
  30. 30.
    Michelson BI, Igel DA, Wilkoff BL. Adequacy of implantable cardioverter-defibrillator lead placement for tachyarrhythmia detection by sinus rhythm electrogram amplitude. Am J Cardiol. 1995;76(16):1162–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Schaumann A, von zur Mühlen F, Herse B, Gonska BD, Kreuzer H. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. Circulation. 1998;97(1):66–74.PubMedCrossRefGoogle Scholar
  32. 32.
    Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM, et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol. 2006;48(2):330–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients results from the PREPARE (primary prevention parameters evaluation) study. J Am Coll Cardiol. 2008;52:541–50.PubMedCrossRefGoogle Scholar
  34. 34.
    Kroll MW. A minimal model of the single capacitor biphasic defibrillation waveform. Pacing Clin Electrophysiol. 1994;17(11 Pt 1):1782–92.PubMedCrossRefGoogle Scholar
  35. 35.
    Kroll MW, Efimov IR, Tchou PJ. Present understanding of shock polarity for internal defibrillation: the obvious and non-obvious clinical implications. Pacing Clin Electrophysiol. 2006;29:1–7.CrossRefGoogle Scholar
  36. 36.
    Poelaert J, Jordaens L, Visser CA, De Clerck C, Herregods L. Transoesophageal echocardiographic evaluation of ventricular function during transvenous defibrillator implantation. Acta Anaesthesiol Scand. 1996;40(8 Pt 1):913–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Runsio M, Bergfeldt L, Brodin LA, Ribeiro A, Samuelsson S, Rosenqvist M. Left ventricular function after repeated episodes of ventricular fibrillation and defibrillation assessed by transoesophageal echocardiography. Eur Heart J. 1997;18(1):124–31.PubMedCrossRefGoogle Scholar
  38. 38.
    Stoddard MF, Redd RR, Buckingham TA, McBride LR, Labovitz AJ. Effects of electrophysiologic testing of the automatic implantable cardioverter-defibrillator on left ventricular systolic function and diastolic filling. Am Heart J. 1991;122(3 Pt 1):714–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Steinbeck G, Dorwarth U, Mattke S, Hoffmann E, Markewitz A, Kaulbach H, et al. Hemodynamic deterioration during ICD implant: predictors of high-risk patients. Am Heart J. 1994;127(4 Pt 2):1064–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Swerdlow CD, Martin DJ, Kass RM, Davie S, Mandel WJ, Gang ES, et al. The zone of vulnerability to T wave shocks in humans. J Cardiovasc Electrophysiol. 1997;8(2):145–54.PubMedCrossRefGoogle Scholar
  41. 41.
    Strickberger SA, Man KC, Souza J, Zivin A, Weiss R, Knight BP, et al. A prospective evaluation of two defibrillation safety margin techniques in patients with low defibrillation energy requirements. J Cardiovasc Electrophysiol. 1998;9(1):41–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Gold MR, Breiter D, Leman R, Rashba EJ, Shorofsky SR, Hahn SJ. Safety of a single successful conversion of ventricular fibrillation before the implantation of cardioverter defibrillators. Pacing Clin Electrophysiol. 2003;26:483–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Wetherbee JN, Chapman PD, Troup PJ, Veseth-Rogers J, Thakur RK, Almassi GH, et al. Long-term internal cardiac defibrillation threshold stability. Pacing Clin Electrophysiol. 1989;12(3):443–50.PubMedCrossRefGoogle Scholar
  44. 44.
    Gold MR, Kavesh NG, Peters RW, Shorofsky SR. Biphasic waveforms prevent the chronic rise of defibrillation thresholds with a transvenous lead system. J Am Coll Cardiol. 1997;30(1):233–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Tokano T, Pelosi F, Flemming M, Horwood L, Souza JJ, Zivin A, et al. Long-term evaluation of the ventricular defibrillation energy requirement. J Cardiovasc Electrophysiol. 1998;9(9):916–20.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of Cardiovascular MedicineHeart and Vascular Institute, Cleveland ClinicClevelandUSA
  2. 2.Medicine Department, Cleveland Clinic Lerner College of MedicineCase Western Reserve UniversityClevelandUSA
  3. 3.Cardiology Department, Cardiac ElectrophysiologySouthern Arizona VA Health Care CenterTucsonUSA
  4. 4.Medicine DepartmentUniversity of ArizonaTucsonUSA

Personalised recommendations